{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:47:53Z","timestamp":1695624473489},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T00:00:00Z","timestamp":1478304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>In recent years, some patients have been unresponsive to anticholinergics used in the treatment of pollakisuria\/urinary incontinence. It has been suggested that propiverine hydrochloride, which has not only anticholinergic activity, but also calcium antagonistic activity, may be useful in poor responders to other anticholinergics. In this study, a specific drug use\u2013results survey was conducted in poor responders to other anticholinergics to evaluate the usefulness of propiverine hydrochloride.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this survey, propiverine hydrochloride was administered for 12\u2009weeks to poor responders to previous anticholinergics, and its usefulness was evaluated by the overactive bladder symptom score (<jats:styled-content style=\"fixed-case\">OABSS<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3851 subjects at 680 institutions were enrolled in the survey. Of the 3624 subjects included in the safety evaluation (male 1899, female 1725, mean age 73.4\u2009years), 2932 were included in the efficacy evaluation (male 1610, female 1322, mean age 73.8\u2009years). Propiverine hydrochloride significantly improved the <jats:styled-content style=\"fixed-case\">OABSS<\/jats:styled-content> without any safety concerns in poor responders to previous anticholinergics (<jats:styled-content style=\"fixed-case\">OABSS<\/jats:styled-content>, 8.22 at baseline, 6.50 at <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>eek 4, 5.87 at <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>eek 8, and 5.57 at <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>eek 12, <jats:italic>P\u2009&lt;<\/jats:italic>\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present findings indicate that propiverine hydrochloride may be a useful therapeutic option for poor responders to previous anticholinergics.<\/jats:p><\/jats:sec>","DOI":"10.1111\/luts.12145","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T12:15:47Z","timestamp":1478348147000},"page":"116-121","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Usefulness of Propiverine Hydrochloride in Poor Responders to Previous Anticholinergics"],"prefix":"10.1111","volume":"10","author":[{"given":"Naoya","family":"MASUMORI","sequence":"first","affiliation":[{"name":"Department of Urology Sapporo Medical University School of Medicine  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"FUNATO","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department Taiho Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunobu","family":"YAMAGUCHI","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department Taiho Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunio","family":"ITOH","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department Taiho Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,5]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Clinical Guidelines for Overactive Bladder","author":"Committee for Clinical Guidelines for Overactive Bladder of Japanese Continence Society","year":"2015"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3100750"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1999.00251.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000020221"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09050.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2011.02732.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1757-5672.2010.00081.x"},{"key":"e_1_2_7_9_1","first-page":"46","article-title":"Efficacy of propiverine hydrochloride for patients with stress and mixed urinary incontinence","volume":"12","author":"Sugaya K","year":"2014","journal-title":"J New Rem Clin"},{"key":"e_1_2_7_10_1","first-page":"145","article-title":"Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder","volume":"94","author":"Haruno A","year":"1989","journal-title":"J Pharmacol Sci"},{"key":"e_1_2_7_11_1","first-page":"53","article-title":"Effect of propiverine on the atropine\u2010resistant contraction of urinary bladders in aged rats","volume":"26","author":"Yamada A","year":"2008","journal-title":"Yamagata Med J"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/714978"},{"key":"e_1_2_7_13_1","first-page":"278","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub\u2010committee of the International Continence Society","volume":"14","author":"Homma Y","year":"2003","journal-title":"J Jpn Continence Soc"},{"key":"e_1_2_7_14_1","first-page":"1023","article-title":"Post marketing surveillance of propiverine hydrochloride (BUP\u20104 tablets) in pollakiuria and urinary incontinence","volume":"30","author":"Itoh K","year":"2002","journal-title":"Jpn Pharmacol Ther"},{"key":"e_1_2_7_15_1","first-page":"37","article-title":"Long\u2010term administration study of propiverine hydrochloride (BUP\u20104 tablets) in pollakisuria and urinary incontinence","volume":"30","author":"Itoh K","year":"2002","journal-title":"Jpn Pharmacol Ther"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fluts.12145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fluts.12145","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:52:21Z","timestamp":1695563541000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.12145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,5]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/luts.12145"],"URL":"https:\/\/doi.org\/10.1111\/luts.12145","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"value":"1757-5664","type":"print"},{"value":"1757-5672","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,5]]}}}